Abcellera Biologics is trading 4.91% down now at $9.28 after a sharp regular-session rally.
- Positive ABCL635 Phase 2 results met both primary efficacy endpoints, showing an 83% reduction in moderate-to-severe hot-flash frequency versus 33% for placebo.
- No new negative company-specific announcement explaining the after-hours decline was identified.
- The move may reflect profit-taking after consecutive gains, a softer Nasdaq, and broader risk-off conditions.